Gilteritinib (ASP2215) is a Potent and ATP-competitive FLT3/AXL Inhibitor for AML Research
Acute myeloid leukemia (AML) is a group of malignant diseases of the hematopoietic system. And, AML occurs as the result of mutations in hematopoietic stem/progenitor cells. Despite advances in treatment, AML remains a challenging disease to manage, with a high relapse rate and poor long-term outcomes. In this article,...